Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Resonac core operating profit more than doubles to ¥88.8 billion in FY26 1H; revenue rises 5% to ¥676.9 billion

Resonac core operating profit more than doubles to ¥88.8 billion in FY26 1H; revenue rises 5% to ¥676.9 billion

ReutersReuters2026/08/06 06:43
  • Resonac posted 2026 first-half revenue of ¥676.9 billion, up 5%, while core operating profit more than doubled to ¥88.8 billion.
  • Profit attributable to owners climbed to ¥48.5 billion, up 147%, while IFRS operating profit rose to ¥73.3 billion from ¥32.6 billion.
  • EBITDA margin improved to 19.8% from 12.8%, while adjusted net D/E ratio fell to 0.65 from 0.83 at June 30.
  • Semiconductor and Electronic Materials revenue rose 30% to ¥299.0 billion, lifting core operating profit 92% to ¥81.5 billion, a quarterly record.
  • Full-year forecast lifted to ¥196.0 billion in core operating profit from ¥140.0 billion, with EBITDA margin seen at 24.4% from 17.9%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Resonac Holdings Corporation published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage